Business
Cingulate is a clinical-stage biopharma company using its PTR platform to develop once-daily, multi-dose tablets for ADHD and anxiety, led by CTx-1301.
Cingulate narrowed cash burn, but losses widened.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage ADHD platformNote
- Revenue — No revenue rowNote
- Net loss — ($22.4M), widerWatch
- FCF — ($17.4M), improved 6.7%OK
- Equity — $2.5M, -66.3%Watch
- Insiders — 4 purchases / 0 salesOK
Leadership changes
From Cingulate Inc.'s own filings, the day they're filed.
- Jeff Hargroves · director · departureeff. 2026-05-18
- Issuance Proposal · member · appointmenteff. 2026-03-27
- Jeff Hargroves · member · appointmenteff. 2026-02-13
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cingulate Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.